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Available online 10 July 2014Abstract Common methods for the generation of human embryonic-derived neural stem cells (hNSCs) result in cells with
potentially compromised safety profiles due to maintenance of cells in conditions containing non-human proteins (e.g. in
bovine serum or on mouse fibroblast feeders). Additionally, sufficient expansion of resulting hNSCs for scaling out or up in a
clinically relevant time frame has proven to be difficult. Here, we report a strategy that produces hNSCs in completely
“Xeno-Free” culture conditions. Furthermore, we have enriched the hNSCs for the cell surface marker CD133 via magnetic
sorting, which has led to an increase in the expansion rate and neuronal fate specification of the hNSCs in vitro. Critically, we
have also confirmed neural lineage specificity upon sorted hNSC transplantation into the immunodeficient NOD-scid mouse
brain. The future use or adaptation of these protocols has the potential to better facilitate the advancement of pre-clinical
strategies from the bench to the bedside.
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Regenerative medicine strategies for central nervous
system (CNS) injury and disease represent a major unmet
clinical need. One approach will likely include theaccess article under the CC BY-NC-ND license
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Indeed, fetal- and embryonic-derived hNSCs are currently
in phase I clinical trials for multiple neurological disorders,
including spinal cord injury (Cummings et al., 2005; Salazar
et al., 2010), Pelizaeus Merzbacher disease (Uchida et al.,
2012), and dry age-related macular degeneration (Schwartz
et al., 2012). However, despite the promise afforded by
these trials, obstacles (including a complicated FDA
approval process for cell lines, difficulties expanding cell
lines sufficiently for human transplantation, and tumorige-
nicity concerns (Germain et al., 2012) resulting from
residual, non-differentiated pluripotent cells) still remain.
Future cell-based strategies using new cell lines will
benefit from the use of protocols designed to produce
readily expandable cell lines with robust safety profiles
during the initial pre-clinical phases of research that
address FDA concerns for clinical compliance. Here, we
report feasible methodologies to generate highly expandable
multipotent hNSCs from human embryonic stem cells (hESCs)
under completely Xeno-Free (XF) and feeder-free culture
conditions. Additionally, we have magnetically sorted the XF
hNSCs to further enrich for a highly proliferative neural stem
population (CD133+) and reduce the potential for non-neural
tumor formation (Tamaki et al., 2002). Together, XF cell
culture methods and population enrichment via cell sorting
may offer a streamlined approach to generate more readily
approvable, expandable, and potentially safer cell popula-
tions for CNS transplantation.
Materials and methods
Human embryonic and neural stem cell
culture and differentiation
Culture of hESC lines Shef3, Shef4, and Shef6 (University
of Sheffield, UK) was established at UC Irvine in accor-
dance with all appropriate hSCRO and IBC protocols on
mitotically-inactivated mouse embryonic fibroblasts (MEFs,
EMD Millipore) and in defined media consisting of KO DMEM/
F12, 20% KO Serum Replacement (KO SR), 0.1 mM NEAA,
2 mM GlutaMAX, 0.1 mM ß-Mercaptoethanol, and 20 ng/mL
bFGF (All from Life Technologies). To transition cells to
Xeno-Free (XF) culture conditions, all non-human animal-
based components (MEFs, KOSR) were removed and re-
placed with human-based or recombinant alternatives
including CELLstart CTS, KO SR Xeno-Free CTS, and KO SR
GF Cocktail CTS (All from Life Technologies). XF hESC
culture media consisted of KO DMEM/F12, 15% KO SR
Xeno-Free CTS, 2 mM GlutaMAX, 1× KO SR GF Cocktail
CTS, 0.1 mM ß-Mercaptoethanol, and 20 ng/mL bFGF. Cells
were manually split every 4–7 days upon reaching ~90%
confluence.
For neuralization, an adapted version of a previously
published “EZ-sphere” based neuralization protocol (Ebert
et al., 2013) was utilized where hESC colonies were manually
detached and cultured as floating spheres in Ultra Low Cell
Culture Flasks (Corning Inc.) and in media consisting of
X-Vivo 15 (Lonza Group Ltd.; Basel, Switzerland), 1× N2,
100 ng/mL bFGF, and 100 ng/mL EGF (Life Technologies).
Spheres were split approximately every 2 weeks via me-
chanical trituration using a wide-end P1000 pipette tip withcare taken to avoid dissociation to single cells. 5 days prior
to adherent monolayer culture, 10 ng/mL LIF (EMD Millipore)
was added to the sphere culture media (Xeno-Free Neural
Stem Media, or XF-NSM). To begin adherent monolayer
culture, spheres were plated onto CELLstart coated plates
in XF-NSM. Within 1–2 days following sphere attachment,
single cells began migrating away from the large sphere and
upon reaching 80–90% confluence were dissociated using
TrypLE Select (Life Technologies) and replated onto
CELLstart coated plates in XF-NSM. Cells were then split in
this manner every 4–6 days. All karyotype analyses of cell
lines were performed off-site (Cell Line Genetics Inc.;
Madison, WI).
For neural differentiation, TrypLE Select dissociated
single cells were plated onto CELLstart coated Lab-Tek
Permanox chamber slides (Thermo Fisher Scientific/Nunc) in
XF-NSM. 24 h after attachment, the media was changed to
differentiation media (DM) consisting of X-Vivo 15, 10 ng/mL
BDNF (Peprotech), 10 ng/mL GDNF (Peprotech), 1× N2, 1×
B27 (Life Technologies), 2 ng/mL Heparin (Sigma-Aldrich;
St. Louis, MO), 63 μg/mL NAC (Sigma-Aldrich), 0.1 ng/mL
bFGF, and 10 μg/mL Ciprofloxacin (Mediatech, Inc.). The
media was changed every 3 days with half being removed
and replaced with fresh DM. Differentiation was carried out
for a total of 2–4 weeks before cells were permeabilized and
immunostained.Magnetic-activated cell sorting and flow
cytometric analysis
Magnetic-Activated Cell Sorting (MACS, Miltenyi Biotec)
was performed using an autoMACS Pro Separator (Miltenyi
Biotec) according to manufacturer-provided protocols via
a two-step process: 1) positive selection of CD133+ cells
(retain), followed one passage later by 2) negative
selection for CD34+ cells (remove), to obtain a CD133+/
CD34− enriched cell population. Human serum albumin
(HSA, Octapharma USA Inc.) was used in place of bovine
serum albumin. Magnetic microbead kits human CD133
microbead kit (130-050-801, Miltenyi Biotec) and human
CD34 microbead kit (130-046-702, Miltenyi Biotec) were
used. All cells were grown prior to sorting as well as
post-sorting on CELLstart coated plates in XF-NSM. TrypLE
was used to dissociate cells prior to sorting.
For flow cytometric analysis, antibodies used were
human CD133/2 (293C3)-PE (130-090-853, Miltenyi Biotec)
and human CD34-FITC (130-081-001, Miltenyi Biotec).
Surface marker staining was performed according to
supplied antibody protocols. Briefly, pelleted cells were
resuspended in 80 μL MACS buffer. 20 μL of FcR Blocking
Reagent and 10 μL of each respective antibody (either
alone, or in combination) were then added to the cell
suspension. The suspension was then mixed and incubated
at 4 °C for 10 min. Following antibody incubation the cells
were washed then incubated with Annexin V according to
manufacturer protocols (Life Technologies) for 15 min at
room temperature. Human IgG beads (BD Biosciences)
were used as fluorescent antibody binding controls. All
flow cytometry analyses were performed using a BD
FACSAria II and FACS Diva and FlowJo (ver. 10.0.6)
software.
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ously (Piltti et al., 2011) with minor modifications. Briefly,
cells were fixed with 4% paraformaldehyde for 15 min and
then permeabilized in PBS containing 0.5% Triton X-100
(Sigma-Aldrich) for 20 min. The cells were then blocked in
PBS containing 5% donkey serum (Jackson ImmunoResearch),
and 1% BSA (Sigma-Aldrich) for 10 min, followed by primary
antibody incubation in blocking buffer for 2 h at room tem-
perature. Primary antibodies included monoclonal mouse anti-
SSEA4 (1:75, ab16287, Abcam), polyclonal rabbit anti-Oct4
(1:200, ab19857, Abcam), polyclonal rabbit anti-Sox2 Alexa
Fluor 488-Conjugated (1:100, AB5603A4, EMD Millipore), mono-
clonal mouse anti-hNestin (1:200, MAB1259, R&D Systems),
monoclonalmouse anti-ßIII Tubulin (1:500,MMS-435P, Covance),
polyclonal rabbit anti-GFAP (1:500, Z0334, DakoCytomation),
and polyclonal goat anti-hOlig2 (1:100, AF2418, R&D Systems).
Following primary antibody incubation and washes, cells were
incubated in appropriate secondary antibodies for 1 h at room
temperature and then mounted with Flouromount-G (Southern-
Biotech) for imaging. Secondary antibodies included: Alexa Fluor
488 Donkey Anti-Rabbit, Alexa Fluor 555 Donkey Anti-Mouse,
Alexa Fluor 488 Donkey Anti-Mouse, Alexa Fluor 568 Donkey
Anti-Rabbit, and Alexa Fluor 647 Donkey Anti-Goat. Hoechst
33342 (H1399) was used for nuclear identification. All secondary
antibodies and Hoechst were from MolecularProbes/Life Tech-
nologies and used at a 1:1000 dilution. All secondary antibodies
were tested for cross-reactivity and non-specific binding.
Imaging was performed using an Olympus FluoView FV10i
(Olympus America Inc.) and a Zeiss Axio Imager.M2 Apotome
System (Carl Zeiss).RNA extraction and PCR analysisTotal RNA was isolated from harvested cells from 2 wells of a
6-well culture plate by scraping with lysis buffer from an
RNeasy mini kit (Qiagen). Extracted total RNA was treated
with RNase free DNase I (DNA free; Ambion), and synthesis of
cDNA was performed by oligo(dT)/random primer mediated
reverse transcription with a minimum of 300 ng of total
RNA input using a high capacity RNA-to-cDNA kit (Applied
Biosystems). For quantitative PCR experiments, each reac-
tion was performed using 100 ng of cDNA with TaqMan®
probe-based gene expression primers that were analyzed per
gene (technical duplicates) in biological triplicate (three
independent experiments) for all samples for each cell
stage in the study. For non-quantitative PCR experiments,
GoTaq Green Master Mix (Promega Corp.) was combined with
specifically designed forward and reverse primers and
200 ng cDNA. PCR conditions used were 95 °C denaturation,
62 °C annealing, and 72 °C extension for either 35 or
40 cycles. Due to the number of comparisons, samples of
the same cycle number were run in parallel across multiple
agarose gels on the same day, and identical exposure
settings were used to capture all gel band images. Images
were then arranged side-by-side in the figure for ease of
visual comparison. All kits were used according to manu-
facturer's instructions. For primers used see Table S1.In vitro cell growth and proliferation analysis
To assess cell growth and obtain mean doubling times of
both non-sorted and CD133+/CD34− hNSCs, cells were
seeded at an initial density of 5 × 105 cells per well onto
CELLstart-coated 6-well plates. Cells were harvested and
dissociated into single cells using TrypLE and counted
manually via Trypan Blue exclusion at 24-, 48-, 72-, 96-,
and 120-h post-plating. All cell growth assays were
performed in biological triplicates. To assess proliferation
via 5-ethynyl-2′-deoxyuridine (EdU, C10337, Life Technol-
ogies) incorporation, cells were plated onto CELLstart
coated Permanox chamber slides and allowed to grow to
approximately 80–90% confluence before adding 10 μM
EdU and incubating for 24 h. Post-EdU incubation, cells
were fixed and EdU incorporation was detected via a
Click-iT® reaction. The quantification of EdU-positive
cells to total number of Hoechst-positve nuclei was per-
formed by analyzing fluorescent images of at least 8
randomly chosen fields from 3 independent experiments
using Volocity 3D Image Analysis Software (PerkinElmer)
(Piltti et al., 2011).Human stem cell preparation for transplantation
All animal housing conditions, surgical procedures, and
postoperative care were approved by and conducted
according to the Institutional Animal Care and Use Commit-
tee (IACUC) guidelines at the University of California, Irvine.
All hESC and hNSC preparations took place during the day of
transplantation/injection. All cells were maintained under
normal culture conditions prior to harvesting and collection
for hippocampal/subcutaneous injection. For hippocampal
hNSC injections, cells were dissociated to single cells using
TrypLE and resuspended in X-Vivo 15 to yield 7.5 × 104 cells/μl.
hESCs were harvested in a similar manner for hippocampal
injection but care was taken to avoid single-cell dissociation by
using a cell scraper (BD Falcon) rather than TrypLE. Hippocam-
pal cell preparations were kept at room temperature.
For subcutaneous leg injections of both hESC and hNSC,
cells were prepared similarly to hippocampal preparations
but were resuspended in Matrigel rather than X-Vivo 15 and
kept on ice to prevent Matrigel from polymerizing pre-
maturely. Dilutions ranged from 1.25 to 2.5 × 106 cells per
50 μl.Intracranial and subcutaneous cell transplantations
For intracranial injections, both male and female NOD-scid
mice (12–20 weeks old; The Jackson Laboratory) were
anesthetized with 2% isoflurane and positioned in a stereo-
taxic holder (Leica Microsystems Inc.). A midline incision was
made exposing the skull. A 5 μl Hamilton syringe (Cat
#87930) with a custom 1″ 30G blunt needle was mounted
into an UMP-3 (World Precision Instruments) injector con-
nected to a SYS-Micro4 Controller. The needle was then
moved to 1.94 mm posterior to bregma and 2.00 mm lateral
to midline, and a mark was made using a mechanical pencil.
The needle was moved out of the way, and a burr hole was
drilled using a Dremel rotary tool at ~5,000 rpm. Cells were
first triturated 5 times with a 10 μl pipette then pulled up
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first lowered to 2.15 mm ventral relative to bregma to
create a pocket in the brain, then raised to 2.10 mm. Cells
were then injected at doses ranging from 7.5 × 104 to
1.5 × 105 (at 7.5 × 104 cells/μl) over 2 min. Speeds varied
relative to the total volume, but time of injection remained
constant. The needle was raised out of the brain 4 min
after injection. The syringe was tested to make sure it was
not clogged by ejecting some of the solution into the air
manually through the Micro4 controller. Bone wax was
applied to seal the burr hole, and the midline incision was
stapled shut.
For subcutaneous injections, anesthetized mice received
50 μl injections of either cells (hESC or hNSC) or vehicle
control (Matrigel, BD Biosciences) via injection through a
23G needle attached to a 1 ml syringe that was inserted
underneath the skin, between the knee and ankle. The
needle was held in place for approximately 10 s before
retraction, and all cell/vehicle preparations, and injection
equipment, were kept on ice to prevent Matrigel from
polymerizing prematurely.
Animals were randomly allocated to different cell type and
injection location groups as described in Table 1 and were
furthermore processed blind to injection cohort. Animals
received lactated ringers (50 ml/kg) subcutaneously immedi-
ately after surgery as well as Buprenorphine (0.5 mg/kg)
immediately after surgery and for 2 days thereafter. Addi-
tionally, due to the immunodeficient nature of NOD-scid
mice, an antibiotic (Baytril, 2.5 mg/kg) was administered
immediately after surgery and daily for 5 days thereafter.
No immunosuppressant drugs were administered to any
animal.Tissue collection and immunohistochemistry
Tissue collection and immunohistochemistry were per-
formed as previously described (Hooshmand et al., 2009)
with minor modifications. Briefly, all animals, ranging from
8 to 20 weeks post-transplant, were anesthetized with a
lethal dose of Euthasol (100 mg/kg, i.p.) and transcardially
perfused with 30 ml of PBS, followed by 100 ml of 4%Table 1 Engraftment and tumorigenesis potential of XF Shef6 hE
Cell line/type Leg injection
dose
# leg
grafts
% with
leg tumors
Shef6 hESC 1,250,000 14 79% (11/14
Shef6 hNSC (unsorted) 1,250,000 10 0% (0/10)
Shef6 hNSC (unsorted)
Shef6 hNSC (sorted) 1,250,000 23 0% (0/23)
Shef6 hNSC (sorted) 2,500,000 17 0% (0/17)
Engraftment and tumor forming potential of subcutaneously (leg) and
both non-sorted and low passage (P7) CD133+/CD34− sorted hNSCs at
(leg) and 63% (CNS) of transplants at 8–12 weeks post-transplant. All an
non-sorted hNSCs were detected 12 weeks post-transplant. CD133+/C
and no CD133+/CD34− sorted Shef6 hNSC transplants resulted in tumparaformaldehyde. Brains were carefully dissected and
post-fixed overnight in a solution of 4% paraformaldehyde
and 20% sucrose in PBS at 4 °C, flash frozen at −65 °C in
isopentane (2-methyl butane), and stored at −80 °C.
For cryosectioning and immunohistochemistry, frozen
brains were embedded in Optimal Cutting temperature
(O.C.T.) compound (Sakura Finetek USA, Inc.). 35 μm thick
coronal sections were cut on a sliding microtome, collected
in 96-well plates containing 0.1 M Tris and 0.02% Sodium
Azide, and kept at 4 °C until processed for immunostaining.
All immunostaining procedures were conducted at room
temperature. Briefly, sections were washed in 0.1 M Tris
followed by a 15 minute incubation in 0.3% hydrogen
peroxide/methanol. After a brief 0.1% Triton X-100 wash,
sections were blocked for 1 h with bovine serum albumin
(BSA) and normal serum from the species in which the
secondary antibody was raised. Sections were then exposed
overnight to the appropriate primary antibody. The primary
antibodies used were: monoclonal mouse anti-SC121 (1:10,
000), monoclonal mouse anti-SC101 (1:2,000), mouse mono-
clonal anti-SC123 (1:3,000) (all from StemCells Inc.), mono-
clonal mouse anti-hNestin (1:1,000) (MAB1259, R&D Systems),
polyclonal rabbit anti-PDX1 (1:2,000) (ab47267, Abcam),
polyclonal rabbit anti-αSMA (1:100) (ab5694, Abcam), mono-
clonal rabbit anti-ßIII Tubulin (1:500) (MRB-435P, Covance),
polyclonal rabbit anti-VGlut1 (1:50, ab72311, Abcam), and
polyclonal rabbit anti-GAD65 + 67 (1:1000, ab49832, Abcam).
The next day, sections were incubated with either
fluorescent or biotin-conjugated, purified IgG secondary
antibody (1:500, Jackson Immunoresearch) pre-adsorbed
against the species in which the primary was raised, fol-
lowed by avidin–biotinylated peroxidase complex (ABC)
using a Vectastain Elite ABC kit (Vector Laboratories, USA)
prepared according to the manufacturer's recommenda-
tions (for DAB staining). After several washes, the signal
was visualized with diaminobenzidine (DAB) (Vector Laborato-
ries, USA). Sections weremounted onto slides and allowed to dry
overnight at 37 °C. DAB stained sections were lightly counter-
stained with the nuclear marker, methyl green. Fluorescent
stained sections were counterstained with Hoechst 33342
(1:1000, Life Technologies). All slides were coverslipped using
Depex or Fluoromount-G (SouthernBiotech) mounting medium.SCs and hNSCs.
CNS injection
dose
# CNS
grafts
% with CNS
engraftment
% with CNS
tumors
) 75,000 8 63% (5/8) 63% (5/8)
75,000 8 0% (0/8) 0% (0/8)
150,000 2 0% (0/2) 0% (0/2)
75,000 15 93% (14/15) 0% (0/15)
150,000 4 100% (4/4) 0% (0/4)
intracranially (hippocampus) injected XF Shef6 hESCs as well as
multiple doses. Shef6 hESC transplants resulted in tumors in 79%
imals with successful CNS hESC engraftment exhibited tumors. No
D34− sorted Shef6 hNSCs engrafted in the CNS at a rate of 93–100%
ors. See also Figure S2.
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(Olympus America Inc.) and also a Zeiss Imager.M2 Apotome
System (Carl Zeiss).Statistical analysis
All qPCR and EdU/growth kinetics data are representative of
three or more individual independent experiments. Grubb's
test (ESD method) was used to eliminate qPCR replicate
statistical outliers. Errors are the standard error (SEM) of
averaged results. EdU data analyzed by one-way ANOVA
(Bonferroni post-hoc) with P b 0.001 using GraphPad Prism
software.Figure 1 hESCs transitioned to XF conditions maintain pluripotenc
for the XF transition and subsequent neuralization of hESCs into bi-
EZ sphere-based protocol. (B–D) Shef3 (B) undifferentiated hESCs w
culture media containing BSA. hESCs were then transitioned to XF con
KO SR GF Cocktail. Following XF transition, hESCs continued to ex
Finally, XF transitioned hESCs were further neuralized to form adher
Subsequent karyotype analysis revealed one chromosomal abnorm
(Shef4, Shef6) hNSC lines. (C) Shef4 and (D) Shef6 hESCs were simila
(hESCs, phase), 100 μm (hESCs, fluorescent) and 50 μm (hNSCs). SeResults
Xeno-Free transition and neuralization of three
human embryonic stem cell linesCulture of the human embryonic stem cell lines Shef3, Shef4,
and Shef6 was initially established in “standard” conditions
that contain both bovine and murine components (Fig. 1B–D,
non-XF hESC). To enhance the clinical applicability of these
human stem cell lines, all hESC lines were transitioned to
“Xeno-Free” conditions in a 1-step simultaneous conversion of
both media (to a human serum-based media) and substrate
(to a human vitronectin-based substrate, CELLstart) (Fig. 1A).y and can be further neuralized to form XF hNSCs. (A) Schematic
and multi-polar neural stem/progenitor-like cells via a modified
ere originally maintained on MEFs and in standard non-XF hESC
ditions utilizing the XF substrate CELLstart and KnockOut SR XF/
press the pluripotency markers Oct4 (red) and SSEA4 (green).
ent XF hNSCs that exhibited characteristic neural morphologies.
ality (Shef3, Chromosome 11) and two karyotypically normal
rly transitioned to XF conditions and neuralized. Scale: 200 μm
e also Figure S1.
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a stabilization period of 1–2 passages post-transition in
which spontaneously differentiating cells were removed via
manual dissection. Following XF transition, all three XF
hESC lines maintained circular, hESC-like colony morphol-
ogies and expressed the pluripotency markers Oct4 and
SSEA4 at both 9–11 passages in XF conditions (Fig. 1B–D, XF
hESC) as well as after prolonged XF hESC culture (Figure
S1D).
After 9 to 11 passages in XF hESC conditions (40–60 days
in culture), transitioned XF hESCs were subsequently sub-
jected to neural induction via EGF/FGF supplementation
to generate intermediate neuralized spheres (Ebert et al.,
2013). Further neuralization of spheres with LIF supple-
mentation and cell attachment on CELLstart generated an
adherent monolayer culture system (Fig. 1A) that produced
cells with bi- and multi-polar neural morphologies (Fig. 1B–
D, XF hNSC). One cell line (Shef3) was determined to be
karyotypically abnormal after XF transition and neurali-
zation (Fig. 1B, karyotype; Figure S1). The other two hNSC
lines (Shef4, Shef6) were karyotypically normal (Fig. 1C–D,
karyotype). Prior to any subsequent in vitro or in vivo
studies, XF adherent hNSCs had, at a minimum, been cul-
tured in XF conditions for over 100 days (40–60 days as XF
hESC, followed by 60+ days as XF hNSC spheres/monolayer),
a time period sufficient to eliminate detectable non-human
molecules (Ludwig et al., 2006; Heiskanen et al., 2007).Magnetically sorted (CD133+/CD34− ) Xeno-Free
Shef6 hNSCs exhibit increased neuronal
differentiation in vitro
Following XF neuralization, magnetic sorting was used to
further enrich one of the hNSC lines, Shef6, for a stem/
progenitor population via positive selection of hNSCs
expressing CD133 and depletion of cells expressing CD34.
Flow cytometric analysis of non-sorted XF Shef6 hNSCs
demonstrated that ~17% expressed CD133, and less than
2% expressed CD34 (Fig. 2A). Post-sorting, the CD133+
proportion increased to ~82%, while CD34 remained at less
than 2% (Fig. 2B). The increase in the CD133+ proportion of
cells was maintained over long-term culture as greater
than 70% of sorted XF Shef6 hNSCs still expressed CD133
after 20 additional passages (P27, Fig. 2C).
Interestingly, while both XF undifferentiated non-sorted
and CD133+/CD34− sorted Shef6 hNSCs expressed the neural
stem and progenitor markers Sox2 and Nestin (Fig. 2D–E),
morphological differences were observed between the two
neuralized populations. Notably, non-sorted cells appeared
larger and more cytoplasmic (Fig. 2D) than sorted cells
(Fig. 2E). Additionally, analysis via qPCR (Fig. 2H) demon-
strated a reduction of pluripotent (Oct4, Nanog) and em-
bryonic germ layer (Brachyury, Desmin, GATA-4, Sox17)
mRNA expression in the neuralized populations compared to
XF Shef6 hESCs. Furthermore, the sorted XF Shef6 hNSCs also
expressed higher levels of neural lineage markers Nestin
(6-fold upregulation in P7 CD133+/CD34− sorted hNSCs,
12.5-fold in P27 sorted hNSCs vs. non-sorted Shef6 hNSCs)
and Pax6 (115-fold upregulation in P7 CD133+/CD34− sorted
hNSCs, 600-fold in P27 sorted hNSCs) as well as smaller
increases in both CD133 and Ki67 expression and a decreasein CD34 expression in comparison to non-sorted XF Shef6
hNSCs.
Differences were also observed between the two popula-
tions in cells undergoing neural differentiation, with non-
sorted cells expressing neuronal Class III ß-Tubulin (ßIII-Tub)
and GFAP in elongated, bipolar cells (Fig. 2F) while CD133+/
CD34− cells expressed primarily ßIII-Tub in densely populat-
ed areas (Fig. 2G) as well as GFAP in sparse but clustered
regions (Figure S1C). Morphologically, in the sorted popula-
tion, ßIII-Tub immunostaining was observed in numerous
spineous bipolar and multipolar neuronal cells and GFAP in
larger, flatter astrocytic cell types. qPCR was used to further
probe the differentiation potential of the two populations.
As observed via ICC, there was an increase in neuronal
differentiation (ßIII-Tub 7-fold upregulation, Dcx 89-fold,
Synapsin 22-fold) in the sorted XF Shef6 hNSCs (P7) in
comparison to non-sorted hNSCs (Fig. 2I). Interestingly,
sorted XF Shef6 hNSCs also exhibited a decrease in glial fate
potential (PDGF-Ra, GalC, CSPG, GFAP) compared to non-
sorted cells, suggesting that CD133+ enrichment at this
developmental stage may bias cells toward a neuronal fate.
Importantly, even though the sorted populations exhibited
enhanced proliferation as detected by Ki67 gene expression
under non-differentiating conditions in comparison to non-
sorted XF Shef6 hNSCs (Fig. 2H), there do not appear to be
significant differences once the hNSCs have undergone dif-
ferentiation (Fig. 2I), suggesting a downregulation of pro-
liferative potential upon differentiation.
Furthermore, regional identity of both the non-sorted
and CD133+/CD34− sorted Shef6 hNSCs was evaluated via
RT-PCR (Fig. 3A–B). Non-sorted Shef6 hNSCs expressed
hindbrain markers GBX2 and KROX20, and lacked forebrain
and forebrain/midbrain marker expression (FOXG1 and
OTX2, respectively). Non-sorted Shef6 hNSCs also lacked
expression or expressed very low levels of the neural stem
cell markers PAX6 and ASCL1 as well as neural rosette markers
PLZF and DACH1. Similarly, both low passage (P7) and high
passage (P27) CD133+/CD34− sorted Shef6 hNSCs expressed
the hindbrain markers GBX2 and KROX20, and also lacked or
had very low expression of forebrain markers FOXG1 and
OTX2. However, the sorted hNSCs exhibited expression of
both neural stem (Pax6, ASCL1) and rosette-specific (PLZF,
DACH1) markers, suggesting that the CD133+/CD34− Shef6
hNSCs are most likely an expanding neural stem-like cell
population possessing a hindbrain regional specification
preference.Magnetically sorted (CD133+/CD34− ) Xeno-Free
Shef6 hNSCs proliferate extensively in vitro
In addition to differences in morphology and differentiation
propensity, differences in proliferation and cellular growth
kinetics were also observed between non-sorted and sorted
XF Shef6 hNSCs. EdU incorporation over a 24-hour period was
used to gauge proliferation of undifferentiated hNSCs, with
21% of non-sorted XF Shef6 hNSCs (Fig. 4A, C) incorporating
EdU compared to 91% of CD133+/CD34− sorted XF Shef6
hNSCs (Fig. 4B, C). EdU incorporation remained consistent
after 20 additional passages of prolonged culture (95%,
Fig. 4C). Additionally, non-sorted Shef6 hNSCs expanded to
~850,000 cells from an initial starting density of 500,000
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Figure 2 Undifferentiated CD133+/CD34− sorted XF Shef6 hNSCs have reduced levels of embryonic/germ layer expression, and
generate fewer glial cells but more neurons after in vitro differentiation. (A–C) Flow cytometric analysis of (A) non-sorted (P7),
(B) low passage (P7) CD133+/CD34− sorted, and (C) high passage (P27) CD133+/CD34− sorted XF Shef6 hNSCs displayed an increase in
CD133+ proportion post-sorting (16.8% to 81.5%, non-sorted to low passage sorted) that was maintained at higher passages (73.0%,
high passage sorted). The CD34+ proportion remained under 5% for all samples. (D-G) Immunocytochemistry of both (D) non-sorted
and (E) low passage CD133+/CD34− sorted XF Shef6 hNSCs expressed neural stem/progenitor markers Sox2 (D–E, green) and Nestin
(D–E, red) in vitro under non-differentiating conditions. Upon differentiation, both (F) non-sorted and (G) low passage CD133+/
CD34− sorted XF Shef6 hNSCs expressed more mature neural lineage markers ßIII-Tub (F–G, green) and GFAP (F, red; Figure S1C, red).
Nuclei were counter-stained with Hoechst 33342 (F–G, blue). Scale: 50 μm (D–G). (H–I) qPCR analysis of (H) embryonic and germ
layer/early differentiation markers expressed in both non-sorted and CD133+/CD34− sorted undifferentiated XF Shef6 hNSCs
normalized to XF Shef6 hESCs and (I) neural lineage differentiation markers expressed in CD133+/CD34− sorted XF Shef6 hNSCs after
28DIV neural differentiation normalized to non-sorted XF Shef6 hNSCs. All data were normalized to internal 18s rRNA and expressed as
mean log2 fold change ± SEM (n = 3 independent experiments with technical duplicates of each independent biological experiment).
220 D.L. Haus et al.cells over the course of 5 days in vitro (Fig. 4D), giving a
doubling time of 5.1–6.4 days. Conversely, over the same
5 day period, CD133+/CD34− sorted Shef6 hNSCs expanded
to over 14 million cells (Fig. 4D) from the same initial
density of 500,000 cells (a doubling time of 0.9–1.4 days).
The overall increase in cell expansion of sorted XF Shef6
hNSCs in comparison to non-sorted XF Shef6 hNSCs was
maintained after 20 additional passages (Fig. 4D), although
a minor decrease in expansion capability was observed
between low (P7, 0.9–1.4 days doubling) and high passage
(P27, 1.0–1.4 day doubling) sorted hNSCs. Interestingly,
non-sorted and CD133+/CD34− sorted Shef4 hNSCs exhi-
bited similar in vitro expansion rates to each other, but
both were slower than the non-sorted Shef6 hNSCs (data
not shown). Due to the slow proliferative nature of the
Shef4 hNSCs, as well as the karyotypic abnormality in theShef3 hNSCs, further in vivo studies utilized Shef6 hNSCs
exclusively.
Taken together, the EdU and growth kinetics data suggest
a dramatic increase in proliferative potential of the sorted
XF Shef6 hNSCs in vitro such that a starting population of
2 million hNSCs could be expanded to over 300 million hNSCs
in ~10 days (Fig. 4E).Xeno-Free CD133+/CD34− sorted hNSCs do not form
teratomas in vivo and differentiate primarily
into neurons
To examine tumorigenicity potential, intrahippocampal trans-
planted non-sorted and CD133+/CD34− sorted Shef6 hNSCs
were compared to similarly transplanted undifferentiated
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Figure 3 CD133+/CD34− sorted Shef6 hNSCs express hindbrain as well as neural stem and rosette-specific transcription factors in
vitro. (A–B) RT-PCR analysis of non-sorted XF Shef6 (P7), low passage (P7) CD133+/CD34− sorted, and high passage (P27) CD133+/
CD34− sorted XF Shef6 hNSCs at (A) 35 cycles of PCR amplification exhibited expression of hindbrain transcription factors GBX2 and
KROX20, and lacked expression of forebrain and forebrain/midbrain factors FOXG1 and OTX2, respectively, as well as the ventral
marker NKX2.2 and the more mature FGF/EGF-expanded marker AQP4. CD133+/CD34− sorted Shef6 hNSCs demonstrated expression
of neural stem cell markers PAX6 and ASCL1, as well as neural rosette markers PLZF and DACH1, whereas non-sorted Shef6 hNSCs
exhibited very low to no expression of these neural stem/rosette markers. (B) At 40 cycles of PCR amplification, CD133+/CD34−
sorted Shef6 hNSCs exhibited very low levels of FOXG1 (P27 hNSCs) and AQP4 expression (P7 and P27), but no or extremely low
expression of OTX2 and NKX2.2.
221CD133-enriched maintenance of hNSC lines in completely XF culture conditionsShef6 hESCs. As expected from a pluripotent cell population,
transplanted Shef6 hESCs exhibited graft overgrowth with
widespread intrahippocampal migration, that in many cases
caused the endogenous tissue architecture to become de-
formed (Fig. 5A). Transplanted Shef6 hESCs also expressed
both neural and non-neural (Fig. 5B–D) germ layer-specific
markers, including hNestin (ectoderm), α-SMA (mesoderm),
and PDX1 (endoderm) at 8 weeks post-transplantation.
Additionally, subcutaneous leg injections of both Shef6
hESC and hNSC populations were performed at doses ranging
from 1.25 million to 2.5 million cells per injection. Only
the Shef6 hESC population displayed gross anatomical abnor-
malities, with 79% of injected animals exhibiting large
masses (Table 1, Figure S2).
Conversely, intrahippocampal transplanted Shef6 hNSCs
(as opposed to Shef6 hESCs) exhibited markedly different
engraftment dynamics. We saw no evidence of cell engraft-
ment in any of the 10 animals transplanted with non-sorted
Shef6 hNSCs (Table 1) at 12 weeks post-transplantation.
Conversely, a high level of engraftment was observed in
CD133+/CD34− Shef6 hNSC transplanted animals (18/19,
95%; Table 1). Engrafted cells migrated laterally from the
single injection site, spanning from the dentate gyrus to CA3
(Fig. 5E). The sorted Shef6 hNSCs extended cell projections
that often displayed bundled or fasciculated phenotypes
(Fig. 5F). Occasionally, cells appeared to migrate out from
hippocampus and were located adjacent to the walls of
the lateral ventricle. Engrafted CD133+/CD34− Shef6 hNSCsexhibited primarily neuronal differentiation at 12 weeks
post-transplantation, determined via co-expression of the
human-specific cytoplasmic marker SC121 and ßIII-Tub
(Fig. 5G). Rare astroglial differentiation was also observed
(SC123; Fig. 5H). Additionally, SC121+ human cells were
nearly always found to be associated with vesicular gluta-
mate transporter 1 (VGlut1) immunopositive neurons
(Fig. 6A–D), suggesting that the majority of the trans-
planted CD133+/CD34− Shef6 hNSCs differentiated into
glutamatergic neurons in vivo. Glutamic acid decarboxyl-
ase (GAD67) positive puncta were also occasionally asso-
ciated with SC121+ human cells, although the pattern of
GAD67 immunoreactivity appeared more isolated, sparse,
and on the surface of SC121+ cells (Fig. 6E–H), suggesting
that the human, glutamatergic neurons were receiving
GABAergic innervation rather than being GABAergic them-
selves. In no cases examined was non-neural cell type
staining found to be co-localized with transplanted human
hNSCs (e.g. α-SMA, PDX1).Discussion
The data presented here establish protocols to transition
and maintain multiple hESC and hNSC lines long-term in
completely XF culture conditions, thus providing straight-
forward methodologies to produce clinically compliant cell
lines. Additionally, we have used magnetic sorting to enrich
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Figure 4 CD133+/CD34− XF Shef6 hNSCs proliferate extensively in vitro. (A–B) Undifferentiated (A) non-sorted (P7) and (B) low
passage (P7) CD133+/CD34− sorted XF Shef6 hNSCs incorporated EdU over a 24-hour pulse period. EdU (A–B, green) and Nestin (A–B,
red). Nuclei were counterstained with Hoechst 33342 (A–B, blue). Scale: 50 μm (A–B). (C) Quantification of EdU incorporation as a
percentage of total cells (EdU + Hoechst+/Hoechst+). Error bars are mean percentage ± SEM (n = 3 independent experiments)
analyzed by ANOVA (Bonferroni), * P b 0.001. (D) Growth kinetics of non-sorted (P7) as well as both low (P7) and high passage (P27)
CD133+/CD34− sorted XF Shef6 hNSCs plated on CELLstart at an initial density of 500,000 cells and cultured for 5 subsequent days.
Cells were counted daily at the same time. Error bars are mean cell counts ± SEM (n = 3 independent experiments). (E) Schematic
example of CD133+/CD34− sorted XF Shef6 hNSC expansion capability to generate in excess of 300 million hNSCs from one thawed
vial (containing 2 million hNSCs) over the course of ~10 days.
222 D.L. Haus et al.these XF Shef6 hNSCs for cells expressing the surface marker
CD133. Sorting for CD133+ cells dramatically increased both
the neuronal fate preference as well as the proliferative
potential of the Shef6 hNSCs, to the extent that enough cells
could potentially be generated within ~10 days for a
theoretical human brain transplant (Gupta et al., 2012).
Importantly, we have also addressed safety concerns
inherent with embryonic stem cell-derived hNSCs. We have
demonstrated that while these cells expand rapidly in
culture, once they are transplanted into the brain there
was no evidence of non-neural lineage tumors. Both XF
human cell types (embryonic and neural) generated via the
methods presented here exhibited good stability. After more
than 10 passages in completely XF conditions, XF hESCs
remained karyotypically normal, expressed key pluripotency
markers, exhibited minimal spontaneous differentiation,
and were able to generate teratomas upon transplantation
into NOD-scid mice. XF transitioned hESCs were subsequent-
ly able to be differentiated into hNSCs in completely XF
conditions as well. CD133+/CD34− XF Shef6 hNSCs were
able to be maintained for over 25 passages in XF neural
conditions, maintained a normal karyotype, exhibitedsimilar differentiation and proliferation profiles to earlier
passage hNSCs, and engrafted after intrahippocampal
transplantation.
Positive selection via magnetic sorting for CD133 increased
the CD133+ proportion of the XF Shef6 hNSCs from 17% to 82%.
Interestingly, the CD34+ proportion of the Shef6 hNSCs was
measured at less than 5%, as detected by flow cytometry,
in both the non-sorted and CD133+/CD34− sorted hNSCs,
which may obviate the need for CD34 depletion in the cell
populations discussed herein. However, CD34 is expressed on
multiple cell types, including hematopoetic stem cells (Civin
et al., 1984; Baumet al., 1992; Goodell et al., 1997), endothe-
lial cells (Pusztaszeri et al., 2006), macrophages (Ryncarz and
Anasetti, 1998), andmicroglia (Asheuer et al., 2004; Ladeby et
al., 2005), and therefore warrants depletion consideration in
future pluripotent-derived neural populations. In this regard,
we have found that CD133+/CD34− sorting has altered the
in vitro fate profile of the hNSCs. Both the non-sorted and
CD133+/CD34− populations similarly expressed neural stem/
progenitor markers Sox2 and Nestin under non-differentiating
conditions. However, the sorted population, under differen-
tiating conditions, appeared to be highly enriched for neurons.
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Figure 5 Evaluation of tumorigenesis potential — in vivo engraftment and fate of hippocampal transplanted XF Shef6 hESC and
CD133+/CD34− sorted XF hNSCs. (A–D) Transplanted XF Shef6 hESCs (dose: 75,000 cells) survive and engraft in the immunodeficient
NOD-scid hippocampus at 8-weeks post-transplantation. (A) Formation of large, dense human-positive (SC121, brown) masses that
engulf the Shef6 hESC transplanted hippocampus. Within the transplanted region, cells of each embryonic germ layer lineage were
detected, including (B) ectoderm (hNestin, green), (C) endoderm (PDX1, green; SC101, red), and (D) mesoderm (α-SMA, red; SC121,
green). Scale: 200 μm (A), 50 μm (B, C), and 80 μm (D). (E–H) Transplanted low passage (P7) CD133+/CD34− sorted XF Shef6 hNSCs
(Dose: 150,000 cells) survive and engraft in the immunodeficient NOD-scid hippocampus at 12-weeks post-transplantation.
(E) Engraftment of Shef6 hNSCs (SC121, brown) and migration into the molecular layer as well as dentate hilar and CA3 hippocampal
regions. (F) Transplanted Shef6 hNSCs often form fibrous bundles that (G) stain positive for the neuronal marker ßIII-Tubulin (ßIII-Tub,
green; SC121, red). (H) Human astrocytes (SC123, red) were also visualized occasionally. For (A, E, and F) methyl green was used to
counterstain nuclei. For (B, D, G, and H) Hoechst 33342 was used to counterstain nuclei (blue). Scale: 200 μm (E), and 20 μm (F–H).
See also Figure S2.
223CD133-enriched maintenance of hNSC lines in completely XF culture conditionsOne possible explanation could relate to the developmental
stage of the hNSCs at the time of cell sorting. Recent evidence
has suggested that the neuralization method utilized in this
study generates very early stage, pre-rosette hNSCs (Ebert et
al., 2013). By sorting for the stemness marker CD133 at this
early stage, we may have enriched the cell population for a
more mitotically active early neural stem cell subtype that
readily generates neuronal lineage cells (Tropepe et al., 2001;
Pruszak et al., 2007; Elkabetz et al., 2008; Koch et al., 2009; Li
et al., 2011; Falk et al., 2012; Yan et al., 2013). Supporting
evidence exists for the derivation of early lineage neural
stem or neuroepithelial-like stem cells that are continuously
expandable in culture, express over 90% CD133 on the cell
surface, and generate predominantly neurons (Koch et al.,
2009; Falk et al., 2012). These cells, termed long-term
self-renewing neuroepithelial-like stem cells or lt-NES cells,
exhibit hindbrain specification but are amenable to region-
al patterning in vitro, engraft after intracranial transplan-
tation and fire action potentials in vivo, and differentiate
predominantly into GABAergic neurons (Steinbeck et al.,
2012). Similarly, the early stage hNSCs generated via the
protocols described herein appeared to be largely hindbrain
specified, though a small glial population was present at least
early in culture (up to passage 7). However, upon intrahip-
pocampal transplantation, CD133+/CD34− XF Shef6 hNSCs gen-
erate predominantly glutamatergic neurons. Regardless, theCD133+/CD34− hNSCs described here represent a population of
stable, self-renewing, and neurogenic early stage neural stem-
like cells that may be of benefit for researchers studying human
neural development.
A second interesting finding was the increased in vitro
proliferation rate of the sorted XF Shef6 hNSCs. CD133+/
CD34− hNSCs have previously been shown to have enhanced
neurosphere forming capabilities (Uchida et al., 2000).
Additionally, some proliferative neuroepithelial cell popula-
tions express CD133 (Pruszak et al., 2007; Falk et al., 2012),
and CD133+ fractions of cancer biopsies and cancer cell lines
have been shown to have increased proliferative rates (Singh
et al., 2003; Kelly et al., 2010). Here, we have demonstrated
that CD133 enrichment of XF Shef6 hNSCs has dramatically
increased their expansion rate, effectively shortening their
doubling time from ~6 days (non-sorted XF Shef6 hNSCs)
to ~1 day (CD133+/CD34− XF Shef6 hNSCs). One possible
explanation for the noted sub-optimal degree of cell growth
and expansion in the non-sorted Shef6 hNSCs could be
heterogeneity in the proportion of slower-cycling or quies-
cent neural stem/progenitor-like cells to faster-cycling
neural stem- or transit amplifying-like cells. Additionally,
non-neural epithelial or multipotent stromal cell types could
be present in the non-sorted population, as evidenced by the
increased level of Desmin mRNA present in the non-sorted
Shef6 hNSCs compared to the CD133+/CD34− sorted hNSCs.
Figure 6 Hippocampal transplanted CD133+/CD34− sorted Shef6 hNSCs predominantly differentiate into glutamatergic neurons
and receive GABAergic inputs. (A–D) Nearly all engrafted CD133+/CD34− Shef6 hNSCs (A, SC121, red) were immunopositive for
vesicular glutamate transporter 1, a glutamatergic neuron marker (B, VGlut1, green), throughout the cytoplasm of the transplanted
cells (C, co-expression; D, magnified inset from C). (E–H) A subset of engrafted CD133+/CD34− Shef6 hNSCs (E, SC121, red) also
appeared to receive glutamic acid decarboxylase (GAD) positive GABAergic inputs (F, GAD67, green), visualized as small GAD67
immunopositive puncta contacting regions of human SC121+ cytoplasm (G, co-expression; H, magnified inset from G). Hoechst 33342
was used to counterstain nuclei (blue). Scale: 20 μm.
224 D.L. Haus et al.The possibility exists then that these slower-cycling, possibly
non-neural cells could be maintaining an overall slower rate
of proliferation via secretion of factors such as BMPs, which
have been shown to decrease NSPC proliferation and induce
cell cycle exit (Liu and Niswander, 2005; Mathieu et al.,
2008). By either enriching for faster-cycling cells or by
eliminating slower-cycling cells (or both) via CD133+/CD34−
cell sorting, we have potentially disengaged the brakes, at
least partially, on this proliferation and cell cycle governing
system in vitro. Moving forward, additional replication of the
above Xeno-Free transition and CD133+/CD34− sorting
studies with multiple different cell lines and cell types,
including human induced pluripotent stem cells, will be
critical to fully evaluate the utility of the methods presented
here across a wide range of human pluripotent and neural
cell types.
However, unabated in vivo cell proliferation can be
problematic and often has undesired consequences such as
tumor formation. CNS transplantation of highly proliferative
hESCs and immature neural progenitors (Brederlau et al.,
2006; Seminatore et al., 2010), as well as known neural
tumor-forming cell lines (Fogh et al., 1977; Pollard et al.,
2009), result in severe over-growth of the host tissue
transplant region. In this study, we transplanted XF Shef6
hESCs into the hippocampus of immunodeficient NOD-scid
mice and find similar results to previous studies — namely,
the hESCs proliferate extensively, differentiate into cell
types of all three embryonic germ layers (form teratomas),and engulf nearly the entire transplant region (hippocam-
pus). Conversely, CD133+/CD34− XF Shef6 hNSCs do not
exhibit transplant region over-growth or non-neural lineage
differentiation. Rather, hippocampal engrafted sorted XF
Shef6 hNSCs tend to distribute more sparsely throughout
the molecular layer, dentate gyrus, and CA3 hippocampal
regions and project fasciculated axon bundles. Interestingly,
using similar cell preparation and transplantation methods,
hippocampal transplanted non-sorted XF Shef6 hNSCs failed
to survive when examined at 12-weeks post-transplant. This
failure could be the result of a combination of different
factors, including, but not limited to, poor cell survival
immediately post-transplant (Okada et al., 2005), insuffi-
cient proliferation of engrafted cells (as opposed to CD133+/
CD34− XF Shef6 hNSCs that are more proliferative in vitro),
and/or delayed cell death (Steinbeck et al., 2012). Future
investigation of both the interactions between the trans-
planted non-sorted cell population and the host transplant
niche, as well as the mechanisms responsible for the ob-
served differences in gene expression and proliferation rate
between the non-sorted and CD133+/CD34− XF Shef6
hNSCs, will be necessary to enhance our understanding of
neural stem cell biology and cell transplantation, and cri-
tically, additional replication of these findings and long-
term survival studies (i.e. 12 months or greater) in the
injured or diseased niche must be performed before final
conclusions can be drawn in regards to cell safety for future
human use.
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